A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Public ClinicalTrials.gov record NCT03400332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Study identification
- NCT ID
- NCT03400332
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 281 participants
Conditions and interventions
Interventions
- BMS-986253 Drug
- Nivolumab Biological
- Ipilimumab Biological
- Placebo Other
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2018 (Actual)
- Primary completion
- Apr 26, 2024 (Actual)
- Completion
- Dec 4, 2025 (Actual)
- Last update posted
- Feb 24, 2026
2018 – 2025
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0059 | Springdale | Arkansas | 72762 | — |
| Local Institution - 0099 | Los Angeles | California | 90033 | — |
| Local Institution - 0007 | Lakewood | Colorado | 80228 | — |
| Local Institution - 0087 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0100 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0101 | Marietta | Georgia | 30060 | — |
| Local Institution - 0012 | Columbia | Maryland | 21044 | — |
| Local Institution - 0003 | Lutherville | Maryland | 21093 | — |
| Local Institution - 0060 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0004 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0076 | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers Of Nevada | Las Vegas | Nevada | 89169 | — |
| Local Institution - 0005 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0032 | New Brunswick | New Jersey | 08903 | — |
| Local Institution - 0025 | New York | New York | 10029 | — |
| Local Institution - 0002 | New York | New York | 10032 | — |
| Local Institution - 0028 | Oklahoma City | Oklahoma | 73104 | — |
| Local Institution - 0017 | Eugene | Oregon | 97401 | — |
| Local Institution - 0001 | Pittsburgh | Pennsylvania | 15213 | — |
| Local Institution - 0009 | Greenville | South Carolina | 29615 | — |
| Local Institution - 0011 | Austin | Texas | 78705 | — |
| Local Institution - 0010 | Dallas | Texas | 75246 | — |
| Local Institution - 0014 | Fort Worth | Texas | 76104-3927 | — |
| Local Institution - 0018 | Houston | Texas | 77030 | — |
| Local Institution - 0006 | San Antonio | Texas | 78240 | — |
| Local Institution - 0013 | Tyler | Texas | 75702 | — |
| Local Institution - 0058 | Salt Lake City | Utah | 84112 | — |
| Local Institution - 0015 | Fairfax | Virginia | 22031 | — |
| Local Institution - 0008 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03400332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03400332 live on ClinicalTrials.gov.